Business
Silo Pharma, Inc. Expands Scientific Advisory Board with the Appointment of Dr. Joshua Woolley of University of California, San Francisco
NEW YORK , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) today announced that its Board of Directors has named scientific research
About this update from Silo Pharma, Inc.
[{"type":"text","content":"NEW YORK , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) today announced that its Board of Directors has named scientific research investigator Dr. Joshua Woolley, M.D. / Ph.D. to its newly formed Scientific Advisory Board. \n Dr. Joshua Woolley M.D. / Ph.D. is an Associate Professor in Residence, Department of Psychiatry at the University of California, San Francisco (UCSF) as well as a staff psychiatrist in Mental Health at the San Francisco Veterans Affairs Medical Center (SFVAMC). Throughout his career, Dr. Woolley has moved between the clinical and research laboratory, focusing his area of study on understanding and treating social cognitive deficits across various mental illness diagnoses. “Dr. Woolley’s commitment to the treatment of psychological and mental disorders is apparent in both his research and his practice,” said Eric Weisblum, CEO of Silo Pharma. “Dr. Woolley’s perspectives will be of tremendous value to us as we continue the advancement of psychedelic drug research and development.” Dr. Woolley is currently the principal investigator and founder of the Bonding and Attunement in Neuropsychiatric Disorders (BAND) Laboratory. The mission of the BAND Lab is to understand the mechanisms of social connection in general, understand why people with mental illness have trouble with social connection, and develop and test novel treatments for these deficits. Dr. Woolley has been studying the mechanisms underlying social cognitive deficits found across different mental illness diagnoses including schizophrenia, posttraumatic stress disorder and substance use disorders. He is also investigating the psychobiological mechanisms underlying group cohesion and trust as well as developing pharmacologically enhanced group interventions for these psychiatric illnesses. “Psilocybin-assisted psychotherapy is showing real promise in research as evidenced by intense interest amongst pharmaceutical companies in new drug therapies,” added Weisblum. “I look forward to working with Dr. Woolley to develop robust research opportunities and contribute to the progress of psychedelic drug research and commercialization.” Dr. Woolley received his bachelor’s degree from Brown University with a double major in Biology and Philosophy. He received both his MD and his PhD in Neuroscience from UCSF. About Silo Pharma Silo Pharma...